Ro48-8684
Ro48-8684 is a water-soluble benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s, which was designed along with Ro48-6791 as an improved replacement for midazolam, but ultimately proved to have little advantages over the parent drug and has not been introduced into clinical practice.[1][2]
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H26FN5O2 |
| Molar mass | 411.472 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
See also
References
- van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, et al. (November 1997). "Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects". British Journal of Clinical Pharmacology. 44 (5): 487–93. doi:10.1046/j.1365-2125.1997.t01-1-00613.x. PMC 2042863. PMID 9384466.
- Albrecht S, Hering W, Ihmsen H, Schwilden H, Schüttler J (October 1999). "[Pharmacokinetic-pharmacodynamic modeling in phase II of drug development. A comparative study with young and old volunteers with benzdiazepine as an example]". Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 34 (10): 634–7. doi:10.1055/s-1999-213. PMID 10548960.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.